Pentraxin 3: A promising therapeutic target for cardiovascular diseases

Ageing Res Rev. 2024 Jan:93:102163. doi: 10.1016/j.arr.2023.102163. Epub 2023 Dec 11.

Abstract

Cardiovascular disease (CVD) is the primary global cause of death, and inflammation is a crucial factor in the development of CVDs. The acute phase inflammatory protein pentraxin 3 (PTX3) is a biomarker reflecting the immune response. Recent research indicates that PTX3 plays a vital role in CVDs and has been investigated as a possible biomarker for CVD in clinical trials. PTX3 is implicated in the progression of CVDs through mechanisms such as exacerbating vascular endothelial dysfunction, affecting angiogenesis, and regulating inflammation and oxidative stress. This review summarized the structure and function of PTX3, focusing on its multifaceted effects on CVDs, such as atherosclerosis, myocardial infarction, and hypertension. This may help in explaining the varying PTX3 functions and usage, as well as in utilizing target organs to manage diseases. Moreover, elucidating the opposite role of PTX3 in the cardiovascular system will demonstrate the therapeutic and predictive potential in human diseases.

Keywords: Atherosclerosis; Biomarkers; Cardiovascular disease; Myocardial infarction; Pentraxin 3.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • C-Reactive Protein / analysis
  • C-Reactive Protein / metabolism
  • Cardiovascular Diseases*
  • Humans
  • Inflammation / metabolism

Substances

  • PTX3 protein
  • C-Reactive Protein
  • Biomarkers